Global Lung Cancer Surgery Market - 2021-2028
発行: DataM Intelligence
ページ情報: 英文 180 Pages
The global lung cancer surgery market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Lung cancer is a fatal lung tumor characterized by the uncontrolled growth of cells in the lung tissues. The analysis of lung cancer is confirmed by biopsy, which is carried out doing CT guidance or bronchoscopy. Lung cancer surgery is the surgical ablation of cancer tissue from the lung. The type of surgery depends upon the size of the tumor and its location inside the lung.
The major factors driving the growth of this market are the growing prevalence of lung cancer, the rising level of pollution, an increasing number of smokers, high awareness levels among the general population about cancer treatment, and continuous developments in surgery equipment are key factors driving the growth of the global lung cancer surgery market.
Rising air pollution in developing countries will drive the market growth
Rising air pollution and people getting affected by it are among the prime factors responsible for the growth of the market for lung cancer surgery. As per an article by the Vital Strategies Environmental Health Division staff, 2018, while most of the 4.2 million premature deaths linked to air pollution are due to heart disease and strokes, around 1.7 million deaths are from lung cancer and other respiratory diseases globally. According to the WHO database, ultra-fine particles of less than 2.5 microns are the highest in India, which has 16 of the world's 30 most polluted cities.
As per recent statistics, lung cancer is around 7.0% of all new cancer cases and almost 9.0% of all cancer-related mortality. There are two main types of carcinomas, non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC). The World Health Organization's (WHO) International Agency for Research on Cancer has stated that outdoor air pollution is a carcinogen or cancer-causing agent. Thus, a rise in air pollution is primarily driving the lung cancer rate, and hence the market is expected to be impacted.
R&D and technological advancement in the treatment of lung cancer is driving the market growth
The rise in R&D and the robot-assisted surgery, minimally invasive surgeries (such as video-assisted thoracoscopic surgeries), and percutaneous trans-catheter surgeries (such as radiofrequency ablation and cryoablation) are advanced surgical procedures that are used in the treatment of lung cancer. Compared to conventional open surgeries, these advanced procedures offer various advantages such as shorter hospital stays, shorter chest tube duration, less blood loss, and smaller incisions. As a result, the preference for these procedures is higher among patients as well as surgeons. Considering the implications of these technological advancements on patient safety, patient comfort, and surgical outcomes, the demand for technologically advanced approaches for lung cancer treatment is expected to increase in the forecast period.
For instance, in March 2019, Intuitive Surgical received clearance for the da Vinci SP surgical system in specific transoral otolaryngology procedures in adults. The FDA cleared the single port approach for lateral oropharyngectomy procedures and tongue-based resection. This technology will enable the invasive experience for complex procedures.
Sortage of well-trained and skilled radiologists and oncologists will hamper the market
However, the high expense of lung cancer surgeries will be a significant market impeding factor. In many emerging and under-developed nations, the patients are incompetent of paying the total expense. Also, some patients have difficulty paying for lung cancer surgeries in developed countries due to unpredictable and unmanageable insurance policies. Hence, high costs and improper insurance coverage will hamper the market growth.
COVID-19 Impact Analysis
The COVID-19 pandemic has impacted the healthcare systems globally and also has a notable impact on the market. As per the article written in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that while the COVID-19 pandemic, there was a 46% reduction in the surgery of the six most prevalent cancer types including lung cancer. Additionally, the Centers for Disease Control and several medical professional organizations suggested that cancer screening and other health prevention services be postponed except the risks outweighed the benefits and ensure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.
Surgical instruments segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
The surgical instruments are expected to account for the largest share of the market. The increasing prevalence of lung cancer across the globe has resulted in a significant increase in the number of lung cancer surgery procedures performed, which is expected to fuel the market for surgical instruments during the forecast period.
For instance, in February 2019, Intuitive Surgical proclaimed that the Food & Drug Administration cleared the Ion endoluminal system to enable minimally invasive biopsy in the peripheral lung. The main aim of Intuitive Surgical is to create plans to begin customer shipments in the second quarter. The Flexible robotic catheter helps the doctors and surgeons to reach the nodules in the peripheral lung.
The growing geriatric population across the globe is one of the key factors expected to propel market growth. According to the CDC statistics, around 60% of all surgical procedures were performed on 45 years and above. These factors are driving the segment growth in the forecast period
Segmentectomy segment are expected to dominate the lung cancer surgery market, by surgical procedures, during the forecast period
Segmentectomy is a standard surgical treatment that can be an option to treat non-small cell lung cancer (NSCLC). It is mainly recommended over lobectomy if the patient already has a highly reduced lung reserve. Although lung segmentectomy has always been famous for resectioning supportive lesions and nonmalignant masses, it is recommended for very early lung cancer. The growing popularity of this technique is because of better outcomes, less pain, and shorter recovery than traditional surgical techniques. Segmentectomy procedure has a reasonable success rate for removing localized tumors and cancers with higher survival rates. The retention of organ functions up to a certain degree and these advantages are anticipated to fuel the studied market growth.
North America region holds the largest market share in the global Lung Cancer Surgery Market
North America region is dominating the global lung cancer surgery market accounted for the largest market share in 2020, owing to the growing incidence of lung cancer in the region, the presence of key market players, and the launch of new commodities influence market growth in the region.
According to the American Cancer Society's estimation, the new lung cancer cases in the United States for 2018 were around 234,030, and about 154,050 deaths were expected due to lung cancer. In the United States, lung cancer survival has been improved, and the incidence of localized lung cancer has increased.
As per the American Lung Association (2018), approximately 541,000 Americans living today have been diagnosed with lung cancer at some point in their lives. The majority of lung cancer patients have been diagnosed within the last five years. Each year, tens of thousands of people are cured of non-small cell lung cancer (NSCLC) in the United States. Lung cancer is primarily a disease of the elderly. It indicates the burden of lung cancer in this country, resulting in the market's growth as there is a high demand for cancer treatment in the United States.
The lung cancer surgery market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Ethicon US LLC, Intutive Surgical Inc, Olympus Corporation, Accuray Inc, AngioDynamics Inc, Teleflex Inc., Shanghai Ezisurg Medical (PRC), SShanghai Bojin Medical Instrument Co., Ltd., (PRC), Taizhou Rich Medical Products Co. (PRC), Ltd., Zhejiang Honsun Medical Technology Co., Ltd. (PRC) among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the lung cancer surgery market globally.
Lung Cancer Surgery Market Key Companies to Watch
Intuitive Surgical Inc.
Overview: Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
Product Portfolio: The Company offers systems, software, instrument, stapling and other surgical items.
Key Development: In March 2019, Intuitive Surgical received clearance for the da Vinci SP surgical system in specific transoral otolaryngology procedures in adults. The FDA cleared the single port approach for lateral oropharyngectomy procedures and tongue-based resection. This technology will enable the invasive experience for complex procedures.
The global lung cancer surgery market report would provide an access to an approx. 61 market data table, 55 figures and 200 pages.
Global Lung Cancer Surgery Market - By Surgical Devices
Cameras and Video Support
Endoscopic Trocars with Optical View
Global Lung Cancer Surgery Market - By Surgical Procedures
Global Lung Cancer Surgery Market - By End User
Global Lung Cancer Surgery Market - By Region
LIST NOT EXHAUSTIVE